Rina M Mbofung, Jodi A McKenzie, Shruti Malu, Min Zhang, Weiyi Peng, Chengwen Liu, Isere Kuiatse, Trang Tieu, Leila Williams, Seram Devi, Emily Ashkin, Chunyu Xu, Lu Huang, Minying Zhang, Amjad H Talukder, Satyendra C Tripathi, Hiep Khong, Nikunj Satani, Florian L Muller, Jason Roszik, Timothy Heffernan, James P Allison, Gregory Lizee, Sam M Hanash, David Proia, Rodabe Amaria, R Eric Davis, Patrick Hwu
T-cell-based immunotherapies are promising treatments for cancer patients. Although durable responses can be achieved in some patients, many patients fail to respond to these therapies, underscoring the need for improvement with combination therapies. From a screen of 850 bioactive compounds, we identify HSP90 inhibitors as candidates for combination with immunotherapy. We show that inhibition of HSP90 with ganetespib enhances T-cell-mediated killing of patient-derived human melanoma cells by their autologous T cells in vitro and potentiates responses to anti-CTLA4 and anti-PD1 therapy in vivo...
September 6, 2017: Nature Communications